Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to shrink head and neck tumors

NCT ID NCT06959082

First seen Feb 27, 2026 · Last updated Jun 18, 2026 · Updated 19 times

Summary

This phase 2 study tests whether adding the experimental drug VS-101 to standard chemoradiotherapy helps shrink tumors in 30 adults with head and neck cancer. Participants are randomly assigned to receive VS-101 plus chemoradiation or chemoradiation alone. The main goal is to see how many patients have their tumors shrink or disappear after 6 and 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cancer Center of Kansas

    RECRUITING

    Wichita, Kansas, 67214, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NYU Langone Health

    RECRUITING

    Manhattan, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.